Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Trastuzumab Plus Pertuzumab Combined With Fulvestrant and Kurmoxilil in HR+/HER2+ Early-Stage Breast Cancer: A Single-Arm Phase II Study

NCT07857226 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT07857226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07857226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Trastuzumab Plus Pertuzumab Combined With Fulvestrant and Kurmoxilil in HR+/HER2+ Early-Stage Breast Cancer: A Single-Arm Phase II Study
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
31 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer